Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 45781K105 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| Novo Nordisk A/S 13G/A Amendment 4 | 0% |
6/22/2026
Event 5/29/2026
|
|
| Novo Nordisk A/S 13G/A Amendment 3 | 5.0% |
4/10/2026
Event 3/31/2026
|
|
| Novo Nordisk A/S 13G/A Amendment 2 | 7.8% |
3/4/2026
Event 12/31/2025
|
|
|
AstraZeneca PLC
13D/A
Amendment 1
|
8.3% |
2/6/2026
Event 12/22/2025
|
|
| AstraZeneca PLC | 8.3% | ||
| MedImmune Limited | 8.3% | ||
| Novo Nordisk A/S 13G/A Amendment 1 | 9.7% |
10/21/2025
Event 7/14/2025
|
|
|
Bpifrance Participations SA
13D/A
Amendment 3
|
7.9% |
5/7/2025
Event 4/25/2025
|
|
| Bpifrance Participations S.A. | 6.9% | ||
| CDC Croissance S.A. | 1.0% | ||
| Caisse des depots et consignations | 7.9% | ||
| EPIC Bpifrance | 6.9% | ||
| Bpifrance S.A. | 6.9% | ||
| Sanofi 13G/A Amendment 1 | 9.1% |
4/29/2025
Event 4/23/2025
|
|
| Sanofi 13G | 9.1% |
4/29/2025
Event 4/23/2025
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|